332 related articles for article (PubMed ID: 11464181)
1. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
2. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
3. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
4. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
5. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.
Vowels BR; Cassin M; Vonderheid EC; Rook AH
J Invest Dermatol; 1992 Jul; 99(1):90-4. PubMed ID: 1607682
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
7. Management of cutaneous T-cell lymphoma: The future is here.
Wood GS
J Am Acad Dermatol; 2001 Aug; 45(2):317. PubMed ID: 11464201
[No Abstract] [Full Text] [Related]
8. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
10. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
11. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
[TBL] [Abstract][Full Text] [Related]
12. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
14. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.
Hahtola S; Tuomela S; Elo L; Häkkinen T; Karenko L; Nedoszytko B; Heikkilä H; Saarialho-Kere U; Roszkiewicz J; Aittokallio T; Lahesmaa R; Ranki A
Clin Cancer Res; 2006 Aug; 12(16):4812-21. PubMed ID: 16914566
[TBL] [Abstract][Full Text] [Related]
15. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
[TBL] [Abstract][Full Text] [Related]
16. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma.
Rook AH; Kubin M; Fox FE; Niu Z; Cassin M; Vowels BR; Gottleib SL; Vonderheid EC; Lessin SR; Trinchieri G
Ann N Y Acad Sci; 1996 Oct; 795():310-8. PubMed ID: 8958942
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.
Rook AH; Prystowsky MB; Cassin M; Boufal M; Lessin SR
Arch Dermatol; 1991 Oct; 127(10):1535-40. PubMed ID: 1929461
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
19. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A
J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199
[TBL] [Abstract][Full Text] [Related]
20. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
